Loading...
Guest User
Welcome! Please login.
| Issue Size (Base) | ₹1000.00 Cr |
| Issue Size (Shelf) | ₹3000.00 Cr |
| Face Value | ₹1000 each NCD |
| Issue Price | ₹1000 per NCD |
| Market Lot | 1 NCD |
| Min Order Qty | 10 NCD |
| Min Order Amount | ₹10000 |
| Listing at | BSE, NSE |
| Tenor | 2 , 3, 5 and 10 years |
| Credit Rating | [ICRA]AA (Stable) by ICRA Limited and CARE AA (Stable) by CARE Ratings Limited |
| Series | Series I to IV |
| Payment Frequency | Anually |
| Period Ended | 30 Mar 2023 | 31 Mar 2022 |
| Assets | 74,436.54 | 84,300.28 |
| Revenue | 9,086.74 | 7,910.89 |
| Profit After Tax | 9,968.58 | 1,998.77 |
| Net Worth | 31,059.00 | 30,120.00 |
| Reserves and Surplus | ||
| Total Borrowing | ||
| Amount in ₹ Crore | ||
The company Promoter is Ajay G. Piramal.
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
| # | Issue Objects |
|---|---|
| 1 | For the purpose of onward lending, financing, and for repayment/prepayment of interest and principal of existing borrowings of the Company - 75% of the amount raised and allotted in this Tranche I Issue. |
| 2 | For General Corporate Purposes - 25% of the amount raised and allotted in this Tranche I Issue. |
| Series 1 | Series 2 | Series 3 | Series 4 | |
|---|---|---|---|---|
| Frequency of Interest Payment | Annual | Annual | Annual | Annual |
| Nature | Secured | Secured | Secured | Secured |
| Tenor | 2 Years | 3 Years | 5 Years | 10 Years |
| Coupon (% per Annum) | 9.00% | 9.05% | 9.20% | 9.35% |
| Effective Yield (% per Annum) | 9.00% | 9.05% | 9.19% | 9.34% |
| Amount on Maturity (In Rs.) | Rs 1,000.00 | Rs 1,000.00 | Rs 1,000.00 | Rs 1,000.00 |
The company has received a rating of [ICRA]AA (Stable) by ICRA Limited and CARE AA (Stable) by CARE Ratings Limited for the NCDs proposed to be issued pursuant to this Issue.
Piramal Enterprises Limited was incorporated in April 1947. The company divides its business activities into the following core business segments: Financial Services, Pharmaceuticals and Healthcare Insights & Analytics. The Financial Services and Pharmaceuticals businesses are further divided into various sub-divisions. The Financial Services business currently includes (i) wholesale lending and (ii) alternative asset management.
They have made strategic investments in Shriram Group which gives us access to a retail lending platform. The Pharmaceuticals business is divided into (i) the Global Pharmaceuticals business, which includes fully integrated end-to-end pharmaceutical development and manufacturing services offerings for other pharmaceutical companies and a portfolio of differentiated branded hospital and generic products, and (ii) the Indian Over-the-Counter Pharmaceuticals business.
The company's global pharmaceuticals business is present in over 110 countries with manufacturing facilities in India, the United States, the United Kingdom and Canada, while its Indian OTC consumer products business has an India-wide distribution network. The Healthcare Insights & Analytics business operates in a niche area of data and technology-driven pharmaceutical and healthcare market research to provide customers across the healthcare value chain with insights into their existing and future business opportunities.
